Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02871726 · ClinicalTrials.gov registry record · NA

Transrectal Ultrasound Robot-Assisted Prostate Biopsy

A NA study of Prostate Cancer, sponsored by Johns Hopkins University.

Recruiting
Registry status
NA
Development phase
483
Enrollment target
1
Study location

NCT02871726: Recruiting NA study of Prostate Cancer, sponsored by Johns Hopkins University.

NCT02871726 is a NA study of Prostate Cancer that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 483 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02871726, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
NA
Development phase
483 participants
Enrollment target
1
Study location

Study Summary

Prostate cancer (PCa) is the most common non-dermatologic malignancy in U.S. men. Transrectal ultrasound (TRUS)-guided prostate biopsy is a commonly used diagnostic procedure for men with an elevated serum prostate-specific antigen (PSA) level and/or abnormal digital rectal examination (DRE). It is estimated that more than 1 million TRUS-guided prostate biopsies are performed annually in the U.S. alone. However, a freehand TRUS-guided systematic biopsy (SB) procedure has significant limitations. First, freehand biopsy cores are often spatially clustered, rather than uniformly distributed, and do not accurately follow the recommended, sextant template. Second, a freehand TRUS-guided biopsy does not allow precise mapping of the biopsy cores within the prostate. Targeted biopsy (TB) using special devices emerged to help the physicians guide the biopsy using multiparametric MRI (mpMRI). TB cores yield a higher cancer detection rate of clinically significance PCa than SB cores, but TB cores also miss a large number of clinically significant PCa that are detected by SB. Accordingly, TB is commonly performed concurrently with SB (TB+SB procedure).

Conditions Studied

Interventions

  • DEVICE TRUS-Robot
  • OTHER TRUS biopsy

Study Locations (1)

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 483 participants
Start Date 2021-11-24
Est. Completion 2026-08
Phase NA

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT02871726

The ClinicalTrials.gov registry entry for NCT02871726 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 483 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (21% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which TRUS-Robot is the first listed.

NCT02871726 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT02871726 about?

NCT02871726 is a clinical study titled "Transrectal Ultrasound Robot-Assisted Prostate Biopsy". Prostate cancer (PCa) is the most common non-dermatologic malignancy in U.S. men. Transrectal ultrasound (TRUS)-guided prostate biopsy is a commonly used diagnostic procedure for men with an elevated serum prostate-specific antigen (PSA) level and/or abnormal digital rectal examination (DRE). It is ...

What is the current status of trial NCT02871726?

This trial is currently recruiting. It is a NA study. The enrollment target is 483 participants. The study started on 2021-11-24. Estimated completion is 2026-08.

What conditions does trial NCT02871726 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT02871726?

The interventions under investigation include: TRUS-Robot (DEVICE), TRUS biopsy (OTHER).

Who is sponsoring clinical trial NCT02871726?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02871726 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.